TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01590368

Intervention type: DEVICE
Group type: OTHER
Intervention: Marketed electrode
Description: 12 electrodes will be placed on the subject for an ECG reading to be taken

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified test electrode
Description: 12 electrodes with modified adhesive will be placed on the subject to allow an ECG reading to be taken
Study: NCT01196897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN LAA Closure Technology (Gen 4.0)
Description: Implantation of the WATCHMAN device into the left atrial appendage.
Study: NCT03349255

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous ET1402L1-CART cells
Description: Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1)-CAR expression construct

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous ET1402L1-CART cells
Description: Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1)-CAR expression construct
Study: NCT01051037

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation
Description: 3 fraction of stereotactic body radiation therapy within 10 days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: Subject will undergo radiofrequency ablation within 10 days of the last fraction of SBRT.
Study: NCT01033084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively and two extra stimulations at week 4 and 6.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively and two extra stimulations at week 4 and 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Patient will receive sertraline 50mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Patient will receive sertraline 50mg/day.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: double placebo
Description: double placebo arm (sham stimulation/placebo pill)
Study: NCT01864083

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission mammography (PEM) When available

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission mammography (PEM) When available

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR
Study: NCT05544435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational İnterviewing
Description: Motivational Interviewing (MI), which is one of these methods, is an individual-based counselling approach that can easily be used by nurses who have been trained to help the management of disease in chronic diseases (Berhe et al., 2020; Kızılırmak \& Demir, 2018; Maslakpak et al., 2020). The core principles of MI includes expressing empathy by providing acceptance and understanding, realizing inconsistencies, avoiding discussions and supporting self-efficacy (Matinolli et al., 2012). The main purpose of MI is to identify the ambivalent emotions that occur in the patient in health-related activities, to strengthen and encourage insights of patients by supporting healthy lifestyle changes and self-confidence (R.Miller \& Rollnick, 2013). Because of its flexibility and ability to be applied in different behavioural aspects, MI can be administered individually and in groups by trained individuals (Maslakpak et al., 2020).
Study: NCT02910141

Intervention type: DEVICE
Intervention: Continuous subcutaneous insulin infusion
Description: Infusion of short-acting insulin from a portable pump
Study: NCT03100448

Intervention type: DEVICE
Group type: OTHER
Intervention: On1 Concept
Description: NobelActive implant placement with simultaneous On1 Base placement
Study: NCT03674658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propafenone
Description: oral, TID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propafenone
Description: oral, TID
Study: NCT00393029

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes
Description: Peripheral blood lymphocytes are harvested by lymphapheresis and engineered to express a T cell receptor that binds to P53.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes
Description: Peripheral blood lymphocytes are harvested by lymphapheresis and engineered to express a T cell receptor that binds to P53.
Study: NCT04101734

Intervention type: DEVICE
Intervention: Double Lumen Endotracheal Tube.
Description: Intubation was performed with Double Lumen Endotracheal Tube.

Intervention type: DEVICE
Intervention: Double Lumen Video Endotracheal Tube.
Description: Intubation was performed with Double Lumen Video Endotracheal Tube.
Study: NCT04086602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IZD334
Description: Active Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IZD334
Description: Active Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo to Match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo to Match
Study: NCT00610285

Intervention type: OTHER
Intervention: Fabrication of thermoplastic face (The Orfit thermoplastic face mask system is routinely used for the treatment of brain and head)
Description: Each patient in the protocol will receive their regularly scheduled SRS treatment plus an additional mock treatment using the non-invasive immobilization system.
Study: NCT04152148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 500mg BAT4306F
Description: Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 750mg BAT4306F
Description: Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 900mg BAT4306F
Description: Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1000mg BAT4306F
Description: Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
Study: NCT02622477

Intervention type: DRUG
Intervention: Pirfenidone
Description: This is an observational study. Pirfenidone is available as an 267 mg capsule for oral administration.
Study: NCT02566811

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal surgery
Description: Hysterectomy defined as an extrafascial hysterectomy whereby the cervix is removed completely but no radical dissection of the parametria is required
Study: NCT01383187

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DE graft and PRP concentrate
Description: Application of DE graft together with PRP concentrate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DE graft
Description: DE grafting presents a standard treatment method in patients with deep-burn trauma.
Study: NCT02566811

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal surgery
Description: Hysterectomy defined as an extrafascial hysterectomy whereby the cervix is removed completely but no radical dissection of the parametria is required

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Description: Bilateral pelvic and para-aortic lymph node dissection
Study: NCT01786681

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive pressure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive pressure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive pressure
Study: NCT00506779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Phase I = Maximum tolerated dose (MTD) derived from dose escalation of 400, 500, 600 mg by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Phase I = Maximum tolerated dose (MTD) derived from dose escalation of 400, 500, 600 mg by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2 by vein over 3 Hours every 21 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2 by vein over 3 Hours every 21 Days
Study: NCT02192567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5573a
Description: Step 1 of this study will use a starting intravenous (IV) dose of 0.1 mg/kg. Eight dose levels are planned, level 1: 0.1 mg/kg, level 1.5: 0.1 mg/kg, 0.3 mg/kg, level 2: 0.3 mg/kg, level 3: 1 mg/kg, level 4: 3 mg/kg, level 5: 10 mg/kg, level 6: 20 mg/kg, level 7: 30 mg/kg.~Step 2: 30 subjects will use the dose determined in Step 1.
Study: NCT02215057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical anesthesia
Description: topical anesthetic drops and Group 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical anesthesia
Description: topical anesthetic drops and Group 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical anesthesia plus intracameral lidocaine 1%
Description: received topical anesthesia plus intracameral lidocaine 1%
Study: NCT00344175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitavastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Study: NCT02695914

Intervention type: DRUG
Intervention: Compound Qingre Granule
Description: A kind of Chinese patent medicine, which is developed by Dr.Shuwen Zhang and Dr.Baoen Wang from Beijing Friendship Hospital.
Study: NCT03371199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride
Description: Sodium chloride tablets, 250 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Starch tablets
Study: NCT01623505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Champix
Description: Participants receiving this treatment will start the medication on the day of the baseline assessment and set a target quit date within the 8 to 14 day period after baseline. Participants in this group will receive a 12-week supply of varenicline. Treatment will begin 2 weeks before the target quit date and continue for 10 weeks after the target quit date. Participants will be prescribed 0.5 mg once daily for 3 days, 0.5 mg twice daily for 4 days, and 1 mg twice daily for 11 weeks. Participants will be given the option of extending their treatment to a maximum of up to 24 weeks of varenicline.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicoderm patch combined with gum or inhaler
Description: Participants receiving this treatment will set a quit date within 2 weeks after baseline assessment and apply the patch on that day. This group will follow the same regimen as the standard patch treatment, but is not limited to a fixed dosing strategy. Participants will be advised on the titration of patch (increase or decrease in dosage) to ensure elimination of withdrawal symptoms (maximum dosage of 35mg/day, maximum treatment of up to 22 weeks). Participants will be provided with either gum or inhaler to manage cravings.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.~\*Off-label dosage approved by Health Canada via No Objection letter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicoderm patch
Description: Participants receiving this treatment group (standard treatment)will set a target quit date within the 2 weeks after baseline assessment and start to apply the patch on that day. This treatment will consist of a 10-week supply of nicotine patches. The initial dosage will be determined from the average number of cigarettes smoked each day as per the manufacturer's recommendation. Participants smoking ≥ 20 cigarettes per day will be prescribed 21 mg/24 hours for 6 weeks, 14 mg/24 hours for 2 weeks, and 7 mg/24 hours for 2 weeks. Participants smoking 11 - 20 cigarettes per day will be prescribed 14 mg/24 hours for 6 weeks, and 7 mg/24 hours for 4 weeks.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.
Study: NCT02232971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Glucagon is given in three different doses according to three research days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Glucagon is given in three different doses according to three research days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Glucagon is given in three different doses according to three research days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline solution
Description: Placebo
Study: NCT04377503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab 180 MG/ML
Description: Tocilizumab 8 mg/kg diluted in 100 ml of saline administered in 60 minutes. The dose will be repeated after 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab 180 MG/ML
Description: Tocilizumab 8 mg/kg diluted in 100 ml of saline administered in 60 minutes. The dose will be repeated after 12 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Sodium Succinate
Description: Patients will receive methylprednisolone at a dose of 1.5 mg / kg / day divided into 2 daily doses for 7 days. Then they will receive 1 mg / kg / day for another 7 days. Finally 0.5 mg / kg / day until 21 days of use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Sodium Succinate
Description: Patients will receive methylprednisolone at a dose of 1.5 mg / kg / day divided into 2 daily doses for 7 days. Then they will receive 1 mg / kg / day for another 7 days. Finally 0.5 mg / kg / day until 21 days of use
Study: NCT01896687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scrambler
Description: Electrotherapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Scrambler
Description: Electrotherapy
Study: NCT04679961

Intervention type: DEVICE
Intervention: ApolloVue® S100 Image System (Apollo Medical Optics)
Description: The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group.

Intervention type: DEVICE
Intervention: ApolloVue® S100 Image System (Apollo Medical Optics)
Description: The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group.
Study: NCT03120364

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP608
Description: Preparation of Oka/SK strain of live, attenuated zoster virus

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: Preparation of Oka/Merck strain of live, attenuated zoster virus
Study: NCT04829266

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: mental simulation
Description: Audio recordings with a mental simulation. The women listened to the text using headphones about 10-15 min before verticalization (5 h after arrival in the postoperative room, about 6 h after anesthesia). In each group, the mental training lasted for about 10 min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mental simulation
Description: Audio recordings with a mental simulation. The women listened to the text using headphones about 10-15 min before verticalization (5 h after arrival in the postoperative room, about 6 h after anesthesia). In each group, the mental training lasted for about 10 min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mental simulation
Description: Audio recordings with a mental simulation. The women listened to the text using headphones about 10-15 min before verticalization (5 h after arrival in the postoperative room, about 6 h after anesthesia). In each group, the mental training lasted for about 10 min.
Study: NCT01611766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Secondary Cytoreductive Surgery
Description: Complete Cytoreduction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salvage Chemotherapy
Description: 6 cycles of postoperative chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salvage Chemotherapy
Description: 6 cycles of postoperative chemotherapy
Study: NCT01084109

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lyophilized meat
Description: Daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cereal
Description: Daily intake of an equi-caloric fortified cereal as complementary feed from 6 to 18 months.
Study: NCT03434418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib
Description: 80 mg oral administration daily
Study: NCT00798577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigamox Ophthalmic Solution
Description: Moxifloxacin 5mg/mL 3 times daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BSS placebo
Description: Balanced Saline Solution for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days
Study: NCT00250406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ureteral Stent
Description: triclosan-eluting ureteral stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteral Stent
Description: Percuflex Plus Stent as the control
Study: NCT03905668

Intervention type: OTHER
Intervention: Video Monitoring
Description: Patients may have video monitoring for up to seven days while in the ICU. The video system will be placed in an unobtrusive area in the patient's ICU room.

Intervention type: OTHER
Intervention: Accelerometer Monitoring
Description: Patients may have accelerometer monitoring for up to seven days while in the ICU. Commercially available accelerometer units, which have been validated in previous clinical studies, will be used.

Intervention type: OTHER
Intervention: Electromyographic Monitoring
Description: Patients may have electromyographic monitoring for up to seven days while in the ICU.

Intervention type: OTHER
Intervention: Noise Level Monitoring
Description: Patients may have noise level monitoring (in decibels) for up to seven days while in the ICU.

Intervention type: OTHER
Intervention: Light Level Monitoring
Description: Patients may have light level monitoring for up to seven days while in the ICU.
Study: NCT04154371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyography-controlled virtual and augmented reality using serious gaming
Description: Surface electrodes and a tracking marker are placed on the subject's affected upper extremity. Electrodes are placed on active muscle sites along the affected extremity determined by palpation. Electrodes are connected to an electromyography recording device, and signal acquisition and processing software are used to record EMG signals and display feedback. Myoelectric signals are used to control a virtual limb on the screen. The intervention consists of different steps: virtual reality, augmented reality, and serious gaming, which the participant must control with their muscle activity, record by EMG, in their affected limb.
Study: NCT03544632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acellular Adipose Tissue (AAT)
Description: Participants (n=15) will be administered between 5cc and 20cc of AAT, depending on their assigned treatment group, via sterile subcutaneous injection into the target defect. The injection is intended to be permanent. After the 3-month study follow-up visit, participants will have the option to undergo additional AAT injection (up to 20cc per treatment) in order to fully correct the defect. Total injected AAT volume per patient will not exceed 40cc. Additional injection is dependent upon study- and patient-specific adverse / unanticipated events to date.~Each vial contains a 2 milliliter (mL) dose of the injectable AAT. This volume is similar to other commonly used injectable filler materials intended for soft tissue correction.
Study: NCT02598505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01672528

Intervention type: OTHER
Intervention: Interview
Description: Patient participates in a face-to-face interview to facilitate development of the new disease specific questionnaire

Intervention type: OTHER
Intervention: Questionnaires
Description: Patients will be sent questionnaires before their procedure, 8 - 12 after their procedure and at 1 and 5 years post procedure